NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球臨床試驗的市場趨勢·市場佔有率·市場規模的預測 (2021-2028年):階段·研究設計·適應症·各地區

Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication, By Region, And Segment Forecasts, 2021 - 2028

出版商 Grand View Research, Inc. 商品編碼 986158
出版日期 內容資訊 英文 120 Pages
商品交期: 2-10個工作天內
價格
全球臨床試驗的市場趨勢·市場佔有率·市場規模的預測 (2021-2028年):階段·研究設計·適應症·各地區 Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication, By Region, And Segment Forecasts, 2021 - 2028
出版日期: 2021年06月09日內容資訊: 英文 120 Pages
簡介

全球臨床試驗的市場規模在預測期間內預計將以5.7%的年複合成長率推移,到2028年達到695億美元的規模。開發治療癌症,呼吸系統疾病,糖尿病和心血管疾病等慢性疾病的新療法需求提升。開發新冠狀病毒感染(COVID-19)治療方法的需求不斷增長,正在推動市場增長。

本報告提供全球臨床試驗的市場調查,彙整市場定義和概要,市場成長的各種影響因素分析,開發平台(管線)趨勢,市場規模的轉變·預測,階段·研究設計·適應症·地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊。

第1章 調查手法·調查範圍

第2章 摘要整理

第3章 市場可變因素·趨勢·展望

  • 市場預測
  • 普及·成長預測製圖
  • 產品平台分析:各階段
  • 貿易快速審批臨床試驗
  • 聯合臨床試驗
  • 虛擬臨床試驗
  • COVID-19的影響
  • 市場動態
  • 市場分析工具

第4章 市場預測·趨勢分析:不同階段

  • 儀表板
  • 市場規模的實際成果·預測
  • 市場佔有率實際成果·預測
  • 階段I
  • 階段II
  • 階段III
  • 階段IV

第5章 市場預測·趨勢分析:各研究設計

  • 儀表板
  • 市場規模的實際成果·預測
  • 市場佔有率實際成果·預測
  • 干預
  • 觀察
  • 擴大存取(點閱)

第6章 市場預測·趨勢分析:各適應症

  • 儀表板
  • 市場規模的實際成果·預測
  • 市場佔有率實際成果·預測
  • 自體免疫/發炎
  • 疼痛管理
  • 腫瘤
  • 中樞神經
  • 糖尿病
  • 肥胖
  • 心臟血管
  • 其他

第7章 市場預測·趨勢分析:各地區·主要國家

  • 儀表板
  • 市場規模的實際成果·預測
  • 市場佔有率實際成果·預測
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
  • 中東·非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第8章 競爭分析

  • 企業簡介
    • IQVIA
    • PAREXEL International Corporation
    • Pharmaceutical Product Development, LLC
    • Charles River Laboratory
    • ICON Plc
    • Wuxi AppTec Inc
    • PRA Health Sciences
    • SGS SA
    • Syneos Health
    • Chiltern International Ltd
    • Eli Lilly and Company
    • Novo Nordisk A/S
    • Pfizer
    • Clinipace
目錄
Product Code: GVR-1-68038-975-3

Clinical Trials Market Growth & Trends

The global clinical trials market size is expected to reach USD 69.3 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.7% from 2021 to 2028. An increase in the volume and complexity of clinical trials has been witnessed lately, which plays an important role in the R&D of new drugs and other products. The market witnessed a decline of 6.0% in 2020 owing to the COVID-19 pandemic. However, the market is projected to recover from 2021 onwards. Also, clinical trials have become increasingly costly ventures, adding to the overall cost of developing a drug. Hence, big pharmaceuticals and small biotechnology firms are looking for innovative ways to improve trial outcomes and decrease operational costs.

The increasing need to develop new therapeutics for chronic diseases such as cancer, respiratory disorder, diabetes, cardiovascular disease, and others is creating immense pressure on healthcare. The global pandemic caused due to COVID-19 and the increasing demand for developing a suitable treatment for the same is driving the market's growth. The number of people affected by the coronavirus has reached one million, which further depicts an increasing need for therapeutics and vaccines. Currently, there are 288therapeutics and 106 vaccines in development. Out of this, nearly 7.0% of therapeutics are in Phase IV, 21.0% in Phase III, and 43.0% and 13.0% in Phase II and Phase I respectively.

The pandemic has also resulted in the global disruption of traditional onsite clinical trials. Hence, regulatory bodies all over the world have launched various initiatives for fast-tracking clinical trials for the development of innovative solutions. One such instance is Solidarity, an international clinical trial launched by the WHO to find effective treatment against COVID-19.

Though COVID-19 is forcing many medical device and drug developers to revise the approach they prepare for these types of crises, integrating best practices within clinical trial procedures and adapting to virtual trials can support the continuous development of therapeutics even in the presence of this pandemic.

Clinical Trials Market Report Highlights

The phase III segment dominated the market and accounted for the largest revenue share of 53.2% in 2020. This is attributed to the complexity level associated with this phase

The interventional segment accounted for the largest revenue share of 82.1% in 2020 owing to the increasing demand for the intervention for clinical trials by researchers

North America dominated the market and accounted for the largest revenue share of 51.0% in 2020. Favorable government initiatives and the presence of large numbers of players in the U.S. offerings advanced services are responsible for market growth

In Asia Pacific, the market is expected to expand at the fastest CAGR of 6.7% over the forecast period owing to the increasing patient pool and cost-efficient services

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Phase
    • 1.1.2. Study Design
    • 1.1.3. Indication
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1: Understanding the market dynamics
    • 1.9.2. Objective 2: Understanding the market estimates and forecasts
    • 1.9.3. Objective 3: Understanding the attributes such as strategy framework, competitor categorization
    • 1.9.4. Objective 4: Understanding the key product and application scopes to conclude on the market size

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Product Pipeline Analysis, by Stage
    • 3.3.1. Therapeutics in development
    • 3.3.2. Vaccines in development
  • 3.4. Fast track of clinical trials
    • 3.4.1. FDA initiative - CTPA
    • 3.4.2. U.K. initiative - ACCORD
    • 3.4.3. ASIA Pacific initiative - DCGI
    • 3.4.4. University of Pittsburgh School of Medicine-UPMC
  • 3.5. Solidarity clinical trials
    • 3.5.1. Participation in solidarity trials
    • 3.5.2. Solidarity clinical trial for vaccines
  • 3.6. Virtual clinical trials
    • 3.6.1. In-home clinical services
  • 3.7. COVID-19 impact on clinical trials
    • 3.7.1. Companies with phase 1 trial disruption
    • 3.7.2. Companies with phase 2 trial disruption
    • 3.7.3. Companies with phase 3 trial disruption
  • 3.8. Market Dynamics
    • 3.8.1. Market Driver Analysis
      • 3.8.1.1. Increasing research and development promoting outsourcing
      • 3.8.1.2. Adoption of new technology in clinical research
      • 3.8.1.3. Increasing prevalence of chronic disease
      • 3.8.1.4. Globalization of clinical trials
    • 3.8.2. Market Restraint Analysis
      • 3.8.2.1. Stringent regulatory policies for patient enrollment
      • 3.8.2.2. Lack of skilled workforce in clinical research
    • 3.8.3. Industry Challenges
      • 3.8.3.1. Rising cost of clinical trial
  • 3.9. Clinical Trials: Market Analysis Tools
    • 3.9.1. Industry Analysis - Porter's
      • 3.9.1.1. Supplier Power
      • 3.9.1.2. Buyer Power
      • 3.9.1.3. Substitution Threat
      • 3.9.1.4. Threat from new entrant
      • 3.9.1.5. Competitive rivalry
    • 3.9.2. PESTEL Analysis
      • 3.9.2.1. Political Landscape
      • 3.9.2.2. Environmental Landscape
      • 3.9.2.3. Social Landscape
      • 3.9.2.4. Technology Landscape
      • 3.9.2.5. Legal Landscape
    • 3.9.3. Major Deals & Strategic Alliances Analysis

Chapter 4. Clinical Trials Market: Segment Analysis, By Phase, 2016-2028 (USD Million)

  • 4.1. Definitions & Scope
  • 4.2. Phase market share analysis, 2020 & 2028
  • 4.3. Segment Dashboard
  • 4.4. Global Clinical Trials Market, by Phase, 2016 to 2028
  • 4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028for the following
    • 4.5.1. Phase I
    • 4.5.2. Phase II
    • 4.5.3. Phase III
    • 4.5.4. Phase IV

Chapter 5. Clinical Trials Market: Segment Analysis, By Study Design, 2016 - 2028 (USD Million)

  • 5.1. Definitions & Scope
  • 5.2. Study Design Market Share Analysis, 2020 & 2028
  • 5.3. Segment Dashboard
  • 5.4. Global Clinical Trials Market, By Study Design, 2016 to 2028
  • 5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
    • 5.5.1. Interventional
    • 5.5.2. Observational
    • 5.5.3. Expanded Access

Chapter 6. Clinical Trials Market: Segment Analysis, By Indication, 2016 - 2028 (USD Million)

  • 6.1. Definitions & Scope
  • 6.2. Indication Market Share Analysis, 2020 & 2028
  • 6.3. Segment Dashboard
  • 6.4. Global Clinical Trials Market, By Indication, 2016 to 2028
  • 6.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
    • 6.5.1. Autoimmune/inflammation
    • 6.5.2. Pain management
    • 6.5.3. Oncology
    • 6.5.4. CNS condition
    • 6.5.5. Diabetes
    • 6.5.6. Obesity
    • 6.5.7. Cardiovascular
    • 6.5.8. Others

Chapter 7. Clinical Trials Market: Segment Analysis, Indication By Study Design, 2016 - 2028 (USD Million)

  • 7.1. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
    • 7.1.1. Autoimmune/inflammation
      • 7.1.1.1. Interventional
      • 7.1.1.2. Observational
      • 7.1.1.3. Expanded Access
    • 7.1.2. Pain management
      • 7.1.2.1. Interventional
      • 7.1.2.2. Observational
      • 7.1.2.3. Expanded Access
    • 7.1.3. Oncology
      • 7.1.3.1. Interventional
      • 7.1.3.2. Observational
      • 7.1.3.3. Expanded Access
    • 7.1.4. CNS condition
      • 7.1.4.1. Interventional
      • 7.1.4.2. Observational
      • 7.1.4.3. Expanded Access
    • 7.1.5. Diabetes
      • 7.1.5.1. Interventional
      • 7.1.5.2. Observational
      • 7.1.5.3. Expanded Access
    • 7.1.6. Obesity
      • 7.1.6.1. Interventional
      • 7.1.6.2. Observational
      • 7.1.6.3. Expanded Access
    • 7.1.7. Cardiovascular
      • 7.1.7.1. Interventional
      • 7.1.7.2. Observational
      • 7.1.7.3. Expanded Access
    • 7.1.8. Others
      • 7.1.8.1. Interventional
      • 7.1.8.2. Observational
      • 7.1.8.3. Expanded Access

Chapter 8. Clinical Trials Market: Regional Market Analysis, By Phase, By Study Design, By Indication, 2016 - 2028 (USD Million)

  • 8.1. Definitions & Scope
  • 8.2. Regional Market Share Analysis, 2020 & 2028
  • 8.3. Regional Market Dashboard
  • 8.4. Regional Market Share, 2020
  • 8.5. Market Size, & Forecasts, and Trend Analysis, 2016 to 2028:
  • 8.6. North America
    • 8.6.1. Market estimates and forecast, by country, 2016 - 2028 (USD Million)
    • 8.6.2. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
    • 8.6.3. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
    • 8.6.4. Market estimates and forecast, By Indication, 2016 - 2028 (USD Million)
    • 8.6.5. U.S.
      • 8.6.5.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.6.5.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.6.5.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.6.6. Canada
      • 8.6.6.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.6.6.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.6.6.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
  • 8.7. Europe
    • 8.7.1. Market estimates and forecast, by country, 2016 - 2028 (USD Million)
    • 8.7.2. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
    • 8.7.3. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
    • 8.7.4. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.7.5. Germany
      • 8.7.5.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.7.5.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.7.5.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.7.6. U.K.
      • 8.7.6.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.7.6.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.7.6.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.7.7. France
      • 8.7.7.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.7.7.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.7.7.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.7.8. Italy
      • 8.7.8.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.7.8.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.7.8.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.7.9. Spain
      • 8.7.9.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.7.9.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.7.9.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
  • 8.8. Asia Pacific
    • 8.8.1. Market estimates and forecast, by country, 2016 - 2028 (USD Million)
    • 8.8.2. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
    • 8.8.3. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
    • 8.8.4. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.8.5. China
      • 8.8.5.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.8.5.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.8.5.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.8.6. Japan
      • 8.8.6.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.8.6.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.8.6.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.8.7. India
      • 8.8.7.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.8.7.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.8.7.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.8.8. Australia
      • 8.8.8.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.8.8.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.8.8.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.8.9. South Korea
      • 8.8.9.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.8.9.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.8.9.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
  • 8.9. Latin America
    • 8.9.1. Market estimates and forecast, by country, 2016 - 2028 (USD Million)
    • 8.9.2. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
    • 8.9.3. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
    • 8.9.4. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.9.5. Brazil
      • 8.9.5.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.9.5.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.9.5.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.9.6. Mexico
      • 8.9.6.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.9.6.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.9.6.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.9.7. Argentina
      • 8.9.7.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.9.7.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.9.7.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.9.8. Colombia
      • 8.9.8.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.9.8.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.9.8.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
  • 8.10. Middle East and Africa
    • 8.10.1. Market estimates and forecast, by country, 2016 - 2028 (USD Million)
    • 8.10.2. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
    • 8.10.3. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
    • 8.10.4. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.10.5. South Africa
      • 8.10.5.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.10.5.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.10.5.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.10.6. Saudi Arabia
      • 8.10.6.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.10.6.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.10.6.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
    • 8.10.7. UAE
      • 8.10.7.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
      • 8.10.7.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
      • 8.10.7.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)

Chapter 9. Clinical Trials Market - Competitive Analysis

  • 9.1. Key companies profiled
    • 9.1.1. IQVIA
      • 9.1.1.1. Company Overview
      • 9.1.1.2. Financial Performance
      • 9.1.1.3. Product Benchmarking
      • 9.1.1.4. Strategic Initiatives
    • 9.1.2. PAREXEL International Corporation
      • 9.1.2.1. Company Overview
      • 9.1.2.2. Financial Performance
      • 9.1.2.3. Product Benchmarking
      • 9.1.2.4. Strategic Initiatives
    • 9.1.3. Pharmaceutical Product Development, LLC
      • 9.1.3.1. Company Overview
      • 9.1.3.2. Financial Performance
      • 9.1.3.3. Product Benchmarking
      • 9.1.3.4. Strategic Initiatives
    • 9.1.4. Charles River Laboratory
      • 9.1.4.1. Company Overview
      • 9.1.4.2. Financial Performance
      • 9.1.4.3. Product Benchmarking
      • 9.1.4.4. Strategic Initiatives
    • 9.1.5. ICON Plc
      • 9.1.5.1. Company Overview
      • 9.1.5.2. Financial Performance
      • 9.1.5.3. Product Benchmarking
      • 9.1.5.4. Strategic Initiatives
    • 9.1.6. Wuxi AppTec Inc
      • 9.1.6.1. Company Overview
      • 9.1.6.2. Financial Performance
      • 9.1.6.3. Product Benchmarking
      • 9.1.6.4. Strategic Initiatives
    • 9.1.7. PRA Health Sciences
      • 9.1.7.1. Company Overview
      • 9.1.7.2. Financial Performance
      • 9.1.7.3. Product Benchmarking
      • 9.1.7.4. Strategic Initiatives
    • 9.1.8. SGS SA
      • 9.1.8.1. Company Overview
      • 9.1.8.2. Financial Performance
      • 9.1.8.3. Product Benchmarking
      • 9.1.8.4. Strategic Initiatives
    • 9.1.9. Syneos Health
      • 9.1.9.1. Company Overview
      • 9.1.9.2. Financial Performance
      • 9.1.9.3. Product Benchmarking
      • 9.1.9.4. Strategic Initiatives
    • 9.1.10. Chiltern International Ltd
      • 9.1.10.1. Company Overview
      • 9.1.10.2. Financial Performance
      • 9.1.10.3. Product Benchmarking
      • 9.1.10.4. Strategic Initiatives
    • 9.1.11. Eli Lilly and Company
      • 9.1.11.1. Company Overview
      • 9.1.11.2. Financial Performance
      • 9.1.11.3. Product Benchmarking
      • 9.1.11.4. Strategic Initiatives
    • 9.1.12. Novo Nordisk A/S
      • 9.1.12.1. Company Overview
      • 9.1.12.2. Financial Performance
      • 9.1.12.3. Product Benchmarking
      • 9.1.12.4. Strategic Initiatives
    • 9.1.13. Pfizer
      • 9.1.13.1. Company Overview
      • 9.1.13.2. Financial Performance
      • 9.1.13.3. Product Benchmarking
      • 9.1.13.4. Strategic Initiatives
    • 9.1.14. Clinipace
      • 9.1.14.1. Company Overview
      • 9.1.14.2. Financial Performance
      • 9.1.14.3. Product Benchmarking
      • 9.1.14.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 Therapeutics in development
  • Table 4 Vaccines in development
  • Table 5 Vaccines in development for COVID-19
  • Table 6 Impact of COVID-19 on new patients entering trials
  • Table 7 Impact of COVID-19 on other therapeutic areas
  • Table 8 Strategic collaborations by key players
  • Table 9 Interventional studies
  • Table 10 Blood cancer clinical trials
  • Table 11 Medicines in development for neurological disorders, 2018
  • Table 12 Number of Alzheimer's disease clinical trials, by phase
  • Table 13 Top 10 therapy areas by phase

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Volume price analysis
  • Fig. 9 Clinical trials market snapshot (2020)
  • Fig. 10 Clinical trials market segmentation
  • Fig. 11 Clinical trials market: Strategy framework
  • Fig. 12 Parent market outlook
  • Fig. 13 Related/ancillary market outlook
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Virtual clinical trials
  • Fig. 16 Companies with affected trials, by size
  • Fig. 17 Affected trials, by study phase
  • Fig. 18 Market driver relevance analysis (Current & future impact)
  • Fig. 19 Market restraint relevance analysis (Current & future impact)
  • Fig. 20 Porter's five forces analysis
  • Fig. 21 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 22 Clinical trials market phase outlook: Segment dashboard
  • Fig. 23 Clinical trials market: Phase movement analysis
  • Fig. 24 Phase I market, 2016 - 2028 (USD Million)
  • Fig. 25 Phase II market, 2016 - 2028 (USD Million)
  • Fig. 26 Phase III market, 2016 - 2028 (USD Million)
  • Fig. 27 Phase IV market, 2016 - 2028 (USD Million)
  • Fig. 28 Clinical trials market study design outlook: Segment dashboard
  • Fig. 29 Clinical trials market: Study design movement analysis
  • Fig. 30 Interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 31 Observational studies market, 2016 - 2028 (USD Million)
  • Fig. 32 Expanded access studies market, 2016 - 2028 (USD Million)
  • Fig. 33 Clinical trials market indication outlook: Segment dashboard
  • Fig. 34 Clinical trials market: Indication movement analysis
  • Fig. 35 Autoimmune clinical trial by phase, 2020 (%)
  • Fig. 36 Autoimmune/inflammation market, 2016 - 2028 (USD Million)
  • Fig. 37 Rheumatoid arthritis clinical trial by phase (%)
  • Fig. 38 Rheumatoid arthritis market, 2016 - 2028 (USD Million)
  • Fig. 39 Multiple sclerosis clinical trial by phase (%)
  • Fig. 40 Multiple sclerosis market, 2016 - 2028 (USD Million)
  • Fig. 41 Osteoarthritis clinical trials by phase (%)
  • Fig. 42 Osteoarthritis market, 2016 - 2028 (USD Million)
  • Fig. 43 Irritable Bowel Syndrome (IBS) market, 2016 - 2028 (USD Million)
  • Fig. 44 Others market, 2016 - 2028 (USD Million)
  • Fig. 45 Pain management market, 2016 - 2028 (USD Million)
  • Fig. 46 Chronic pain clinical trial by phase (%)
  • Fig. 47 Chronic pain market, 2016 - 2028 (USD Million)
  • Fig. 48 Acute pain clinical trial by phase (%)
  • Fig. 49 Acute pain market, 2016 - 2028 (USD Million)
  • Fig. 50 Oncology market, 2016 - 2028 (USD Million)
  • Fig. 51 Blood cancer market, 2016 - 2028 (USD Million)
  • Fig. 52 Solid tumors market, 2016 - 2028 (USD Million)
  • Fig. 53 Others market, 2016 - 2028 (USD Million)
  • Fig. 54 CNS conditions market, 2016 - 2028 (USD Million)
  • Fig. 55 Epilepsy market, 2016 - 2028 (USD Million)
  • Fig. 56 Parkinson's disease (PD) market, 2016 - 2028 (USD Million)
  • Fig. 57 Huntington's disease market, 2016 - 2028 (USD Million)
  • Fig. 58 Stroke market, 2016 - 2028 (USD Million)
  • Fig. 59 Traumatic Brain Injury (TBI) market, 2016 - 2028 (USD Million)
  • Fig. 60 Amyotrophic lateral sclerosis (ALS) market, 2016 - 2028 (USD Million)
  • Fig. 61 Muscle regeneration market, 2016 - 2028 (USD Million)
  • Fig. 62 Others market, 2016 - 2028 (USD Million)
  • Fig. 63 Diabetes market, 2016 - 2028 (USD Million)
  • Fig. 64 Obesity clinical trial by phase (%)
  • Fig. 65 Obesity market, 2016 - 2028 (USD Million)
  • Fig. 66 Cardiovascular market, 2016 - 2028 (USD Million)
  • Fig. 67 Others indications market, 2016 - 2028 (USD Million)
  • Fig. 68 Autoimmune/inflammation interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 69 Autoimmune/inflammation observational studies market, 2016 - 2028 (USD Million)
  • Fig. 70 Autoimmune/inflammation expanded access market, 2016 - 2028 (USD Million)
  • Fig. 71 Pain management interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 72 Pain management observational studies market, 2016 - 2028 (USD Million)
  • Fig. 73 Pain management expanded access market, 2016 - 2028 (USD Million)
  • Fig. 74 Oncology interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 75 Oncology observational studies market, 2016 - 2028 (USD Million)
  • Fig. 76 Oncology expanded access market, 2016 - 2028 (USD Million)
  • Fig. 77 CNS conditions interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 78 CNS conditions observational studies market, 2016 - 2028 (USD Million)
  • Fig. 79 CNS conditions expanded access market, 2016 - 2028 (USD Million)
  • Fig. 80 Diabetes interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 81 Diabetes observational studies market, 2016 - 2028 (USD Million)
  • Fig. 82 Diabetes expanded access market, 2016 - 2028 (USD Million)
  • Fig. 83 Obesity interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 84 Obesity observational studies market, 2016 - 2028 (USD Million)
  • Fig. 85 Obesity expanded access market, 2016 - 2028 (USD Million)
  • Fig. 86 Cardiovascular interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 87 Cardiovascular observational studies market, 2016 - 2028 (USD Million)
  • Fig. 88 Cardiovascular expanded access market, 2016 - 2028 (USD Million)
  • Fig. 89 Others interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 90 Others observational studies market, 2016 - 2028 (USD Million)
  • Fig. 91 Others expanded access market, 2016 - 2028 (USD Million)
  • Fig. 92 Regional market: Key takeaways
  • Fig. 93 Regional market share, 2020
  • Fig. 94 Regional outlook, 2020 & 2028
  • Fig. 95 North America market, 2016 - 2028 (USD Million)
  • Fig. 96 U.S. market, 2016 - 2028 (USD Million)
  • Fig. 97 Canada market, 2016 - 2028 (USD Million)
  • Fig. 98 Europe market, 2016 - 2028 (USD Million)
  • Fig. 99 U.K. market, 2016 - 2028 (USD Million)
  • Fig. 100 Germany market, 2016 - 2028 (USD Million)
  • Fig. 101 France market, 2016 - 2028 (USD Million)
  • Fig. 102 Italy market, 2016 - 2028 (USD Million)
  • Fig. 103 Spain market, 2016 - 2028 (USD Million)
  • Fig. 104 Asia Pacific market, 2016 - 2028 (USD Million)
  • Fig. 105 India market, 2016 - 2028 (USD Million)
  • Fig. 106 Japan market, 2016 - 2028 (USD Million)
  • Fig. 107 China market, 2016 - 2028 (USD Million)
  • Fig. 108 Australia market, 2016 - 2028 (USD Million)
  • Fig. 109 South Korea market, 2016 - 2028 (USD Million)
  • Fig. 110 Latin America market, 2016 - 2028 (USD Million)
  • Fig. 111 Brazil market, 2016 - 2028 (USD Million)
  • Fig. 112 Mexico market, 2016 - 2028 (USD Million)
  • Fig. 113 Argentina market, 2016 - 2028 (USD Million)
  • Fig. 114 Colombia market, 2016 - 2028 (USD Million)
  • Fig. 115 MEA market, 2016 - 2028 (USD Million)
  • Fig. 116 South Africa market, 2016 - 2028 (USD Million)
  • Fig. 117 Saudi Arabia market, 2016 - 2028 (USD Million)
  • Fig. 118 UAE market, 2016 - 2028 (USD Million)